
Aldosterone synthase inhibitors - Pipeline Insight, 2024
Description
Aldosterone synthase inhibitors - Pipeline Insight, 2024
DelveInsight’s, “Aldosterone synthase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Aldosterone synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Aldosterone synthase inhibitors: Overview
Aldosterone synthase (CYP11β2) is the terminal enzyme in the aldosterone biosynthetic pathway and is required for aldosterone biosynthesis. Inactivating mutations in aldosterone synthase induce Na+ wasting, hypotension and hyperkalemia in a rare autosomal recessive syndrome in humans. Increased aldosterone production is the pathophysiologic mechanism of primary aldosteronism, a prominent cause of secondary hypertension, suppressed PRA and hypokalemic metabolic alkalosis. Because aldosterone synthase (AS) is a key enzyme involved in the final three rate-limiting steps of the biosynthesis pathway of aldosterone, therefore its inhibition has been considered as an effective strategy to treat hypertension, heart failure, and related cardio-metabolic diseases.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Aldosterone synthase inhibitors R&D. The therapies under development are focused on novel approaches for Aldosterone synthase inhibitors.
This segment of the Aldosterone synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aldosterone synthase inhibitors Emerging Drugs
- MLS 101: Mineralys Therapeutics
- DP13: Damian Pharma
Further product details are provided in the report……..
Aldosterone synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Aldosterone synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Aldosterone synthase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Aldosterone synthase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aldosterone synthase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aldosterone synthase inhibitors drugs.
Aldosterone synthase inhibitors Report Insights
- Aldosterone synthase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Aldosterone synthase inhibitors drugs?
- How many Aldosterone synthase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aldosterone synthase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aldosterone synthase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Aldosterone synthase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mineralys Therapeutics
- DAMIAN PHARMA AG
- CinCor Pharma
- Laekna Therapeutics
- Angion Biomedica
- PhaseBio Pharmaceuticals
- MLS 101
- DP13
- CIN 107
- LAE 001
- PB 6440
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Aldosterone synthase inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Aldosterone synthase inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MLS 101: Mineralys Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I and I/II)
- Comparative Analysis
- LAE 001: Laekna Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- PB 6440: PhaseBio Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Aldosterone synthase inhibitors Key Companies
- Aldosterone synthase inhibitors Key Products
- Aldosterone synthase inhibitors- Unmet Needs
- Aldosterone synthase inhibitors- Market Drivers and Barriers
- Aldosterone synthase inhibitors- Future Perspectives and Conclusion
- Aldosterone synthase inhibitors Analyst Views
- Aldosterone synthase inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.